Contact Information:

(812) 856-3650
fzhang@indiana.edu
Chemistry A667
Zhang Group Website

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Morbi lacinia. Quisque semper. In rhoncus ante vitae justo. Praesent blandit erat. Morbi lorem. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Aliquam quis pede sit amet justo aliquam interdum. Pellentesque malesuada. Nam vehicula. Maecenas pharetra ultrices arcu. Curabitur malesuada ultricies turpis. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Maecenas volutpat accumsan erat. Maecenas tristique magna tempor nisl. Aenean leo. Mauris non eros in mauris congue tristique. Fusce auctor. Donec luctus malesuada elit.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Morbi lacinia. Quisque semper. In rhoncus ante vitae justo. Praesent blandit erat. Morbi lorem. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Aliquam quis pede sit amet justo aliquam interdum. Pellentesque malesuada. Nam vehicula. Maecenas pharetra ultrices arcu. Curabitur malesuada ultricies turpis.

Research

Professor Zhang's research interests are in biochemistry, chemical genomics, computational chemistry, and structure-based drug design. The Zhang group will solve crystal structures of protein complexes in fat cell signaling and tumor angiogenesis pathways to aid the design of anti-obesity and anti-cancer drugs.

Publications

Hamdouchi C, Zhong B, Mendoza J, Zhang F et al. (2005), Structure-Based Design of a New Class of Highly Selective Aminoimidazo[1,2-]pyridine-Based Inhibitors of Cyclin Dependent Kinases, bioorganic & Medicinal Chemistry Letters.

Jaramillo C, Zhang F. et al (2004), Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation, bioorganic & Medicinal Chemistry Letters.

J. Singh, J. Yingling, Zhang F, et al (2004), Transforming the TGF- pathway: Convergence of distinct lead generation strategies on a novel kinase pharmcophroe for TbRI, Current Opinion in Drug Discovery and Development 7(4): 10-20.

Al-Awar RS, Ray JE, Zhang F. etal (2004). Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors. Bioorg Med Chem Lett. 14(15): 3925-8.

Sawyer JS, Beight DW, Zhang F, Yingling JM (2004). Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett. 14(13): 3581-4.

Hadouchi C, Keyser H, Zhang F, Brooks H, et al (2004). The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo(1,2-a]pyridines. Molecular Cancer Therapeutics. 3(1):1-9

Vincent J.-P, Johnson RB, Parsons S, Zhang F, Wang QM (2003). Identification of a C-terminal regulatory motif in hepatitis C virus RNA-dependent RNA polymerase: structural and biochemical analysis. J. Virology. 77: 9020-9028

Sanchez-Martinez C, Shih C, Zhu G, Dempsey JA, Zhang F (2003) . Studies on Cyclin Dependent Kinase Inhibitors:Indolo[2,3-a]pyrrolo[3,4-c]carbazoles versus Bis-indolylmaleimides, Bioorganic & Medicinal Chemistry Letters 13:3841-3846.

Vieth M, Brooks H, Hamdouchi C, McMillen W, Sawyer JS, Yingling J, and Zhang F(2003). Combining Medicinal Chemistry with Chemogenomic and Computer-Aided Structure-Based Design in Development of Novel Kinase Inhibitors, Cell. Mol. Biol. Lett 8 (2A):566-567

Sawyer JS, Herron DK, Edward CR, Zhang F, and Yingling J (2003). Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-beta Type I Receptor Kinase Domain. Journal of Medicinal Chemistry 46 (19):3953-3956.

Wang QM, Hockman M, Staschke K, Zhang F, Parsons S (2002). Oligomerization and Cooperative RNA Synthesis Activity of HCV RNA-Dependent RNA Polymerase, J. Virology. 76:3865-3872

Jin L, Briggs S, Clawson D, Schevitz R, Smiley D, Tashjian A, Zhang F (2000). "Crystal Structure of Human Parathyroid Hormone 1-34 at 0.9 Å Resolution", J. Biol. Chem. 275:27238-27244.

Zhang F, Basinski M, DiMarchi RD et al. (1997) "Crystal Structure of the Obese Protein Leptin-E100", Nature 387:206-209

Zhang J, Zhang F, Ebert D, Cobb MH, and Goldsmith EJ(1995) "Activity of the MAP Kinase ERK2 is Controlled by a Flexible Surface Loop", Structure 3:299-307.

Zhang F, Strand A, Robbins D, Cobb MH, and Goldsmith EJ (1994) "Crystal Structure of MAP kinase ERK2 at 2.3Å Resolution". Nature. 367: 704-711.

Zhang F, Robbins D, Cobb MH and Goldsmith EJ (1993) " Crystallization and Preliminary X-ray Studies of Extracellular Signal-regulated Kinase-2/MAP kinase with an Incorporated His-tag". J. Mol.Biol. 233: 550-552.

Lin Z, Li J , Zhang F and Tsou C-L (1993) "Structure of D-Glyceraldehyde-3-phosphate Dehydrogenase from Palinurus Versicolor Carrying the fluorescent NAD Derivatives at 2.7 Å Resolution" Arch. Biochem. Biophy. 302:161-166.

Zhang F, Kobe B, Stewart CB, Rutter W and Goldsmith EJ (1991) " Structural Evolution of an Enzyme Specificity: The Structure of Rat Carboxypeptidase A2 at 1.9 Å Resolution". J. Biol. Chem. 266: 24606-24612.

Awards

• 2005-Pre Associate Professor, Department of Chemistry and Biochemistry Program, Indiana University, Bloomington, IN
• 2002-2004 Head, Global Drug Discovery and Development Statistics and Information Sciences, Eli Lilly and Company, Indianapolis, IN
• 1994-2002 Senior Research Scientist, Structural Biology and Drug Design, Eli Lilly and Company, Indianapolis, IN
• 1992-1994 Research Faculty Member, Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
• 1990-1992 Postdoctoral Fellow, Structural Biology, Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
• 1989-1990 Visiting Scientist, High resolution protein crystallography, Photon Factory, Japan
• 1997 Global R&D Community Award, Eli Lilly and Co.
• 1999 Lilly Research Lab President's Recognition Award, Eli Lilly and Co.
• 1990-192 Welch Foundation Fellowship Award

Highlights